Retatrutide: The Next Generation GLP-1

 Retatrutide: Triple-Action. Powerful Results. The Next Generation of GLP Weight Loss Medications

By NovaGenix Health & Wellness •  Updated June 2026

Retatrutide: Could This Be the Most Effective Weight Loss Medication Yet?

If you've been following the world of medical weight loss over the past few years, you already know how dramatically GLP-1 medications like semaglutide and tirzepatide have changed the landscape. You cant turn on the TV or look at social media without seeing their advertisements everywhere. Now, there's a new medication on the horizon that's generating serious buzz in obesity medicine, and the early data is genuinely remarkable. You haven’t heard about it in the mainstream yet, but it’s right around the corner and it’s the next big thing.

Retatrutide isn't approved yet, which is why it’s still relatively unknown, but what researchers are seeing in clinical trials has physicians and patients paying close attention. Here's what you need to know about what’s next on the horizon of weight loss medications.

 

What Is Retatrutide?

Retatrutide (LY3437943) is an experimental weight loss medication made by Eli Lilly, the same large pharmaceutical company that brought developed Mounjaro and Zepbound. Lilly's scientists spent years developing and testing it in the lab before the first human trials began around 2020–2021, and by 2023 the results were impressive enough to be published in two of the world's most prestigious medical journals, the NEJM and The Lancet. It's currently in large-scale Phase 3 trials, with a potential FDA submission expected as early as late 2026 or 2027. When this happens it will take the weight loss world over by storm as it will most likely be the most effective medication that the market has ever seen. What sets Retatrutide apart from every other weight loss medication on the market is that it targets three separate hormone receptors in the body at once, rather than just one or two, like semaglutide and tirzepatide:

•      GLP-1 (Glucagon-Like Peptide-1), reduces appetite and slows stomach emptying

•      GIP (Glucose-Dependent Insulinotropic Polypeptide), enhances insulin secretion and fat metabolism

•      Glucagon Receptor, increases calorie burning and promotes fat oxidation

That third receptor, glucagon, is the key differentiator between it and the other GLP’s. While semaglutide and tirzepatide primarily help people eat less, Retatrutide appears to also increase how many calories the body burns at rest. That combination may explain why its clinical results have outpaced everything that came before it.

You may see it referred to online as a "GLP-3" medication, an informal nickname for triple-receptor agonists. There's no actual GLP-3 hormone, but the shorthand has stuck.

 

What the Research Shows

Phase 2 Trials

So far, early results published in The New England Journal of Medicine were pretty remarkable. After just 48 weeks, participants taking the highest dose lost an average of 24% of their body weight, without a plateau in sight by the end of the study. Blood pressure, cholesterol, triglycerides, and insulin resistance all improved significantly. Perhaps most surprisingly, many participants saw dramatic reductions in liver fat, with a large percentage returning to completely normal liver fat levels. The implications this can have on overall health is profound.

Phase 3 TRIUMPH Trials

The results from the ongoing TRIUMPH trials have been even more striking. Phase 3 is the final and most rigorous stage of clinical testing before a drug can be submitted for FDA approval — it involves large numbers of real patients across multiple locations, and is designed to confirm that what worked in earlier, smaller studies holds up at scale. TRIUMPH is simply the name Eli Lilly gave to their collection of Phase 3 retatrutide studies, each one looking at a different group of patients or health condition.

In one major study involving adults with obesity and knee osteoarthritis, participants on the highest dose lost an average of nearly 29% of their body weight after 68 weeks, currently among the highest figures ever reported in pharmaceutical obesity research. Knee pain improved, mobility increased, and inflammatory markers dropped alongside the weight.

For context, semaglutide (Wegovy) produces roughly 15–17% weight loss on average, and tirzepatide reaches about 20–23%. Retatrutide appears to clear both by a a significant amount.

Type 2 Diabetes

Retatrutide has also shown strong results in patients with Type 2 diabetes, including significant A1C reductions and continued weight loss throughout the study period. Researchers believe it could become an important treatment option for metabolic health well beyond obesity alone. GLP-1 medications were actually first developed to treat Type 2 diabetes long before anyone realized how dramatically they could affect body weight. It turns out that the weight loss was initially discovered as a welcome side effect. Retatrutide continues that tradition, showing strong results in diabetic patients including significant lowering of A1C (a key measure of long-term blood sugar control) and sustained weight loss throughout the study period.

 

How It Compares to Current Medications

Here's a quick side-by-side of how Retatrutide stacks up against existing options:

•      Semaglutide (Ozempic/Wegovy): GLP-1 only | ~15–17% weight loss | FDA approved

•      Tirzepatide (Mounjaro/Zepbound): GLP-1 + GIP | ~20–23% weight loss | FDA approved

•      Retatrutide: GLP-1 + GIP + Glucagon | up to ~29% weight loss | Investigational (Phase 3)

The addition of glucagon receptor activation is what sets Retatrutide apart, it doesn't just suppress appetite, it appears to rev up the body's metabolic engine at the same time.

 

Side Effects and What to Watch For

Like other GLP-1 class medications, most side effects on these medications are gastrointestinal in nature and tend to be most noticeable during dose increases. These include nausea, vomiting, diarrhea, constipation, and early fullness after meals. Most patients report that symptoms improve as the body adjusts, and the clinical trials used a slow titration schedule specifically to minimize these issues which seems to work best as a prescribing strategy for all GLP type medications to reduce unwanted symptoms.

One newly observed side effect drawing attention in Phase 3 studies is dysesthesia, abnormal skin sensations like tingling, burning, or heightened sensitivity to touch. Most cases were mild and didn't require stopping treatment, but researchers are continuing to monitor it to see if this an area of concern or just a rare occurance.

As with other medications in this class, Retatrutide is not appropriate for individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia Type 2 (MEN2).

 

Dosing Used in Clinical Trials

There is no FDA-approved dosing schedule yet. Clinical trials followed a gradual escalation protocol to improve tolerability:

•      Weeks 1–4: 2 mg weekly

•      Weeks 5–8: 4 mg weekly

•      Weeks 9–12: 6 mg weekly

•      Weeks 13–16: 9 mg weekly (when appropriate)

•      Maintenance: up to 12 mg weekly

Patients had doses increased to the next higher level after tolerating the previous amount of medication comfortably, an approach that meaningfully reduced dropouts due to side effects. Slower titration helps to decrease the occurrence of symptoms and maintains patient adherence to protocol, making it the preferred method for long term success

 

Beyond the Scale: What Else Improves

One of the most exciting aspects of Retatrutide’s clinical data for patients, providers and researchers alike isn't just the weight loss numbers were seeing, it's what happens to the rest of the body as well.

Fatty liver disease (formally known as MASLD) showed dramatic improvement amongst trial participants, and many participants also achieved normal liver fat levels during clinical trials, highlighting Retatrutide's potential to support both metabolic health and liver wellness. This likely results from a combination of overall weight loss, improved insulin sensitivity, and the direct effect of glucagon receptor activation on liver fat metabolism, something earlier GLP-1 medications don't provide as well as this does.

Body composition studies also showed that most of the weight lost came from fat mass, particularly visceral abdominal fat, rather than lean tissue, a critical distinction for long-term metabolic health. Many patients NEED to lose weight however it’s preferable to maintain muscle mass Patients are still encouraged to prioritize protein intake and resistance training to preserve muscle during treatment as well as stay well hydrated.

 

A Note for Patients on TRT

Many of our patients an NovaGenix are on hormone replacement therapy. No clinical trials have specifically evaluated Retatrutide alongside testosterone replacement therapy as of yet, but it's worth noting that significant weight loss can meaningfully change hormone metabolism. Patients on TRT who pursue any GLP-1 class medication should continue regular lab monitoring, including total and free testosterone, estradiol, and potentially look at other metabolic panels, throughout treatment to ensure no changes have occurred that could be easily mitigated. At NovaGenix, physician-supervised hormone optimization with Dr. Timothy W. Mackey is always individualized based on current labs and how a patient is responding to both the medications as well as what the blood work reveals.

 

When Will Retatrutide Be Available?

Great question that depends on several different factors. As of mid-2026, Retatrutide remains investigational and cannot be legally prescribed outside approved clinical research studies. The TRIUMPH trial program is ongoing, and regulatory submission could follow completion of the current program, though no firm timeline has been announced by Eli Lilly.

In the meantime, patients should avoid purchasing products marketed as Retatrutide from research chemical websites or unregulated online suppliers. Purity, sterility, and dosing cannot be verified through those channels. We hear from patients all the time about how they were able to purchase these medications from illegal online pharmacies and research h websites but this is ill-advised. An NBC News Article estimated that nearly half of all online pharmacies are operating illegally, so be very careful about who you work with.

 

The Bottom Line

Retatrutide represents a genuine leap forward in weight loss/obesity medicine. It will be huge, I have no doubt about that. By combining three complementary metabolic pathways into a single weekly injection, it has produced weight-loss results that exceed every currently approved medication, while also improving liver health, blood sugar, and cardiovascular risk markers in ways that go beyond appetite suppression alone. It’s going to be a true game changer once approved and legal for prescription use from a certified healthcare professional.

For now we'll just have to continue tracking the both the clinical data and legislative efforts closely. In the meantime, if you're interested in physician-supervised medical weight loss, including currently available options like semaglutide and tirzepatide, as well as complementary therapies like lipotropic injections and targeted fat-loss treatments, the team at NovaGenix is here to help you build a personalized plan based on what's available now and what your individual health goals require. Call to set up a time to speak with Dr. Mackey today.

 

Further Reading & References

•  Retatrutide Phase 2 Trial , NEJM (2023)

•  TRIUMPH Phase 3 Program Overview , ClinicalTrials.gov

•  Eli Lilly Retatrutide Pipeline Information

•  GLP-1 Support at NovaGenix: Protecting Muscle & Metabolism

 

Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Retatrutide has not been approved by the FDA. Always consult a qualified healthcare professional before starting, stopping, or changing any medication or treatment program.